Fidelity Disruptive Medicine ETF (NASDAQ:FMED) Short Interest Down 65.6% in March

Fidelity Disruptive Medicine ETF (NASDAQ:FMED) was the recipient of a large decline in short interest in March. As of March 13th, there was short interest totaling 889 shares, a decline of 65.6% from the February 26th total of 2,586 shares. Currently, 0.0% of the company’s stock are sold short. Based on an average trading volume of 10,559 shares, the short-interest ratio is presently 0.1 days.

Fidelity Disruptive Medicine ETF Price Performance

Shares of FMED traded down $0.02 during mid-day trading on Thursday, hitting $24.37. 1,566 shares of the company’s stock were exchanged, compared to its average volume of 7,287. Fidelity Disruptive Medicine ETF has a 52 week low of $20.69 and a 52 week high of $29.07. The company has a market cap of $56.05 million, a PE ratio of 41.33 and a beta of 1.00. The company has a 50-day simple moving average of $25.91 and a 200 day simple moving average of $26.35.

Institutional Investors Weigh In On Fidelity Disruptive Medicine ETF

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Virtu Financial LLC acquired a new position in shares of Fidelity Disruptive Medicine ETF during the 4th quarter worth about $228,000. Jane Street Group LLC increased its position in shares of Fidelity Disruptive Medicine ETF by 95.4% in the fourth quarter. Jane Street Group LLC now owns 91,414 shares of the company’s stock valued at $2,473,000 after acquiring an additional 44,630 shares during the last quarter. Vise Technologies Inc. acquired a new stake in shares of Fidelity Disruptive Medicine ETF in the fourth quarter valued at about $234,000. Glass Jacobson Investment Advisors llc raised its holdings in Fidelity Disruptive Medicine ETF by 44.0% during the fourth quarter. Glass Jacobson Investment Advisors llc now owns 1,260 shares of the company’s stock worth $34,000 after acquiring an additional 385 shares in the last quarter. Finally, BXM Wealth LLC acquired a new position in Fidelity Disruptive Medicine ETF during the fourth quarter valued at approximately $243,000.

Fidelity Disruptive Medicine ETF Company Profile

The Fidelity Disruptive Medicine ETF (FMED) is an exchange-traded fund that mostly invests in health care equity. The fund is an actively managed fund that invests in companies involved in disruptive innovation in Health Care. The fund invests in securities of domestic and foreign issuers FMED was launched on Apr 16, 2020 and is managed by Fidelity.